Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Purdue already said thanks but no thanks
proof of that?
Aug 04, 2004
Elite Pharmaceuticals Announces Exclusive Option To License Its Technology Granted To Purdue Pharma Has Lapsed
Northvale, New Jersey, Wednesday, August 04, 2004: Elite Pharmaceuticals, Inc. (AMEX:ELI) today announced that the exclusive right to negotiate a license from Elite’s wholly owned subsidiary, Elite Laboratories, Inc., for Elite’s proprietary abuse resistance technology for oxycodone, previously granted to Purdue Pharma L.P., has lapsed. With the inaction of Purdue with respect to this option, the exclusivity granted to Purdue has terminated and Elite intends to recommence negotiations to license its proprietary abuse resistance technology to other companies.
Record Date of Thursday, January 17, 2019, and a Payment Date of Monday, February 25, 2019
You are waiting for the wrong announcement...
Looks like we have a winner here. Pushing into the sweet spot on the chart. Come on cbd partner announcement.
40000 shares dumped right at the close. Painting the tape for some reason.
Very, very well done.
To understand what goes through the minds and bodies of opioid users, The New York Times spent months interviewing users, family members and addiction experts. Using their insights, we created a visual representation of how the strong lure of these powerful drugs can hijack the brain.
A drug like heroin creates a tidal wave in the reward circuits of the brain. To an outsider, it looks as though you have passed out. But on the inside you feel like a master of the universe, like you’re being “hugged by Jesus,” as one user said; there’s peace in your skin and not a single feeling of pain.
You may remember this exact moment for years to come: where you were, what you wore, what you saw and what you heard. You may chase this feeling for years.
Have been told by a healthcare professional that Percocet prescripts are way down. Not being prescribed anymore according to this individual. This person told me that anyone saying otherwise is not telling the truth.
anyone saying otherwise is not telling the truth.
The shortage was caused in the first place because DEA drastically cut national quotas in 2017 and 2018 without any change in demand or prescriptions.
We continue to be troubled by the paucity of scientific and medical support for this three-year trend that has resulted in a dramatic decrease in quotas for much needed pain medicine. Continuing to generally blame the opioid crisis for such reductions is in our opinion short-sighted and pre-supposes that simply reducing the amount of available inventory will reduce abuse and diversion. Moreover, we do not believe the DEA or DOJ is showing appropriate concern for legitimate patients and the impact on medical care.
The proposed APQ reductions in 2019 of the six opioids equate to between seven percent (morphine for sale) and 15 percent (oxymorphone for sale) compared to 2018 levels. DEA reduced the APQs for these opioids minimally in 2018, but had reduced them in 2017 by at least 27 percent of 2016 levels, with hydrocodone, fentanyl, morphine and oxymorphone levels reduced by at least 40 percent. The 2017 APQ reductions eliminated a 25 percent buffer that DEA had added to APQs annually between 2013 and 2016 to guard against shortages.
In order to launch a CII product you have to apply for a quota from the DEA, but you cannot apply for a quota until approval. This request can take several weeks sometimes
Requests for additional raw ingredients were made to the DEA Jan. 1, but partial approvals for Fresenius Kabi and West-Ward Pharmaceuticals, along with a third smaller and unidentified manufacturer, weren't granted until mid-February and mid-March. The process highlights the difficult balance regulators must strike between limiting the opioid epidemic and getting pain medication to critically ill patients. Regulatory hurdles can also throw a wrench in the entire process.
Meanwhile, providers have had to scramble to find adequate alternatives that can sedate patients before surgery and manage pain after an operation as well as treat trauma, burn and cancer patients. Or, in some cases, they have had to put off treatment altogether.
"I am shocked that the DEA raised the quota only three weeks ago after being notified of the significant shortage and inability of Pfizer to ship product," said Erin Fox, who directs the University of Utah's Drug Information Service, adding that it takes time for manufacturers to ramp up production. "The shortage was well known to the DEA, so I am unclear on why it took so long to increase the amounts to other manufacturers."
Info from the conference call in December which sounds like they have sufficient data to move forward with the product(s):
Excellagen is a highly purified, collagen-based gel, extracellular matrix, which has been shown to be substantially more effective than the standard of care using only one to two treatments.
The matrix study showed 68 percent more activity than the standard of care for wounds less than 3 square centimeters and 194 percent greater than standard of care for larger wounds. Equally as important is the speed at which Excellent reduces wound size. After only one application, Excellagen reduced the wound size by 362 percent over standard of care in the matrix study.
Impressive and Robust
Dr. Kirsner, one of the Principal Investigators for the pivotal trial of Excellagen, and a lead author of the publication, presented findings of the MATRIX Study, published in the peer-reviewed Journal of Wound Repair and Regeneration (Wound Rep Reg (2011)19 302-308). Dr. Kirsner emphasized the “impressive healing rates obtained in the study,” and commented on the “the robust quality of the data” obtained in the MATRIX Study, which is the only randomized clinical trial that has been conducted in both the collagen and flowable markets.
The numerically greater complete closure incidence over SOC observed in the GAM501 and FCG groups was not statistically significant; whether the lack of significance was due to small sample size could be determined by future studies.
The finding that 35 of 113 (31%) patients were excluded
when the primary data was photographs is noteworthy.
Still pumpy, but better.
The spin-out will be accomplished by the issuance of one or more dividends of NuGenerex Immuno-Oncology stock to Generex stockholders. The record dates in respect of such dividends are yet to be determined and will be announced in due course. The stock dividends will enable Generex stockholders to directly participate in the promising future of NuGenerex Immuno-Oncology as well as create a large shareholder base with the potential for substantial liquidity on an immediate basis. That liquidity will be further enhanced should NuGenerex Immuno-Oncology be successful in attaining a national stock exchange listing, and should provide NuGenerex Immuno-Oncology with ready access to the capital markets to finance its on-going clinical and regulatory initiatives.
It is collagen which has shown significant help in wound repair and is being used widely. Time will tell if there is a need for this product.
Funny about the PUMP remark. The last press release was back on 12/20 when they released this:
Generex Biotechnology Partner Olaregen Therapeutix Inc. Establishes Sales Force and Distribution Team for the Commercial Launch of Excellagen
Reads like straight forward communication to me with not much "PUMP" to it.
I imagine the could release news everyday if they wanted to. That might be pumping.
Generex Biotechnology Partner Olaregen Therapeutix Inc. Signs Manufacturing Agreements for Excellagen® Wound Healing Collagen Matrix
Business Wire January 03, 2019
Sounds like GNBT has tried to help but communication between you and Todd has been an issue. Why did you choose not to call Todd as he requested? Have you reached out to the transfer agent?
scientists recognize the importance of the zebrafish as a biological model system. Been that way for decades, best to keep up with the SCIENCE
Our findings in zebrafish reflect preliminary clinical findings for rasagiline and minocycline.
and while I am correcting the record here from a medical perspective, it is important to point out that the phase 2 study of isradipine was a safety and, tolerability study, not efficiacy
sorry that is NOT the same quote, LOL talk about easy.
https://www.nature.com/articles/ncomms2149#ref-link-section-12
The predominant (~90%) LTCC in the brain has a CaV1.2 subunit; this channel also is abundant in a variety of peripheral organ systems, including the cardiovascular system and is effectively antagonized by DHPs, accounting for their therapeutic efficacy in hypertension15. However, the LTCC responsible for mitochondrial oxidant stress and increased vulnerability in SNc dopaminergic neurons is largely attributable to expression of LTCCs with a CaV1.3 subunit5,6. Among the DHPs, isradipine has the highest relative affinity for CaV1.3 LTCCs, but it is still CaV1.2 LTCC selective14.
receptor affinity is a starting point in most successful drug development programs, but we know that selectivity, bioavailability, PK etc all contribute to the usefulness (or not) of a drug.
Here is a snippet of usefull info:
The problem with DHPs from a therapeutic perspective, however, is that they are not selective12. LTCCs are a heterogenous class of multi-subunit ion channels13,14 that can be divided into four classes based on the identity of their pore-forming alpha 1 subunit, CaV1.1-4. This pore-forming subunit governs key features of the channel, including gating and pharmacology. The predominant (~90%) LTCC in the brain has a CaV1.2 subunit; this channel also is abundant in a variety of peripheral organ systems, including the cardiovascular system and is effectively antagonized by DHPs, accounting for their therapeutic efficacy in hypertension15. However, the LTCC responsible for mitochondrial oxidant stress and increased vulnerability in SNc dopaminergic neurons is largely attributable to expression of LTCCs with a CaV1.3 subunit5,6. Among the DHPs, isradipine has the highest relative affinity for CaV1.3 LTCCs, but it is still CaV1.2 LTCC selective14. This diminishes the therapeutic potential of DHPs in PD, as cardiovascular side effects limit the dosing and antagonism of CaV1.3 LTCCs. As there are no selective CaV1.3 LTCC antagonists known, there is a real translational need to develop a new therapeutic agent.
The antagonistic effects of well-known LTCC antagonists16,17, like isradipine, verapamil and diltiazem (Fig. 1a), were investigated with
receptor affinity is a starting point in most successful drug development programs, but we know that selectivity, bioavailability, PK etc all contribute to the usefulness (or not) of a drug.
Here is a snippet of usefull info:
In medicine, we know that it is quite rare that only one theory of disease intervention is correct.
It's all relative.
Nothing in either of your posts disputes the science of isradipine over all other CCB's for PD. Isradipine has the highest affinity for CaV1.3 relative to CaV1.2. All other CCBs, even those which cross the blood brain barrier and have some affinity for CaV1.3, are inferior to isradipine because of the higher affinity for CaV1.3 vs. CaV1.2. That means any other CCB is more likely to lower a patient's blood pressure, even if it is neuroprotective. That's why isradipine is the **ONLY** CCB to have a Phase 2 and Phase 3 study for Parkinson's Disease. And that's why isradipine will be the **ONLY** CCB that will be Rx'ed for PD.
Sorry, we all know this is incorrect.
If the study is positive, there may be a small increase in isradipine sales, but also other CCBs will increase. As I have pointed out, this effect is not unique to Isradipine
At a cost of $23 million for the Phase 3, not to mention multiple millions $$ more for Phase 2, isradipine was not chosen by accident. The calcium channel sub-type (Cav1.3) that is associated with damage to dopaminergic neurons in Parkinson's Disease has a stronger affinity for isradipine than any other CCB's. Other drugs are weaker inhibitors of Cav1.3, and so the therapeutic cardiovascular effect (lower BP) outweighs the neuro-protective effect. Isradipine was the best of the bunch, and the purpose of the isradipine Phase 2 study was to establish the highest dose of isradipine that could be well-tolerated in PD patients without too many side effects due to low BP. They tested 2.5mg BID, 5mg BID, and 10mg BID, and they found the 5mg dose to be the best. This dose has been well-tolerated in the STEADY-PDIII study, with 98% retention rate despite the long 36-month study.
The predominant (~90%) LTCC in the brain has a CaV1.2 subunit; this channel also is abundant in a variety of peripheral organ systems, including the cardiovascular system and is effectively antagonized by DHPs, accounting for their therapeutic efficacy in hypertension15. However, the LTCC responsible for mitochondrial oxidant stress and increased vulnerability in SNc dopaminergic neurons is largely attributable to expression of LTCCs with a CaV1.3 subunit5,6. Among the DHPs, isradipine has the highest relative affinity for CaV1.3 LTCCs, but it is still CaV1.2 LTCC selective14..
Follow the shares.
BUT, what about shorting a stock as a business tactic????
Maybe there is a competitor trying to suppress ELTP stock to slow its grow and availability of funding or even to try to drive out of business.
SCHED 13D -- December 31, 2015
Aggregate Amount Beneficially Owned By Each Reporting Person
Ashok G. Nigalaye---40,494,165
Jeenarine Narine----24,665,536
Ram Potti-----------11,594,073
Elite Pharmaceuticals Announces Changes To Their Board Of Directors
NORTHVALE, N.J., April 12, 2016
Mr. Narine tendered his resignation as part of the acquisition of Epic Pharma LLC by Humanwell Healthcare USA, LLC. Mr. Narine is one of the founding members of Epic Pharma.
Tuesday, 04/19/16 07:43:45 PM
ELTP a total POS headed much lower.
Disregard charts at your own peril.
What makes Elites SequestOx any different or any better than any other ADF’s?
In a way, yes...
This thing seems pretty explosive .
“ as any other”.... do all other ADF’s prevent chewing, snorting and injections?.. I don’t think so...
but the average pain patient has just the same risk of becoming addicted to opioids with Elite's capsule as any other
Revenues won't do anything for the stock.
It's all about our pipeline and the ART products.
Stock was trading at .40+ for an ENTIRE YEAR with HALF the annual revenue we're getting now.............What the F does that tell you?????
NOBODY CARES about revenue.
It's the pipeline and ART products!!!!!
Huh?
Never said it didn't, just referring to a post made by another member who said that NEWS, rather honest, fake or manipulation doesn't drive up or lower stock prices.
Think whatever you want.
Then how did Elite get up to .97 at one time then Weez??????
News of Sequest Ox, so I think your wrong here Weez and Gman is right.
Nonsense
Name me another Stock with 5 approvals in the same calendar year where the share price has remained flat or range bound. Targeted manipulation...
Another interesting point about those lists...
https://www.lowestmed.com/top-100-drugs-lists/
Not only does ELTP own ANDA's for the top 3 drugs filled without insurance coverage, but also amlodipine is in the top 10 on both lists. I have a buttload of patients who take amlodipine for blood pressure, and if STEADYPD-III is positive, I will change a goodly number of those scripts to isradipine. I love using generic drugs that have multiple benefits, and in the next few months, we will hear if isradipine fits that description. Why would I continue to prescribe a calcium channel blocker that only decreases blood pressure when I could prescribe a different calcium channel blocker that lowers BP and also protects against neurological damage? The STEADY results are all I'm waiting for, and as soon as positive results are available, I will start prescribing it. I will not need to wait for FDA to say anything about it. I'll just start prescribing isradipine instead of amlodipine for BP, and I bet a lot of PCP's will eventually be doing the exact same thing.
Divy shares arrived at Schwab.
Both the brokerage and Rollover IRA accts went from 100 to 2100 shares. The share price went from 18.99 to .9043, the market value is unchanged at $1899, and both are designated to see footnote #6.
6. The value reported may not reflect the current price.
What may be happening today is any institutional holder of IPCI is closing their position.
Making up fantasy exit points to make one look not as bad is funny. LOL.
If I had bought any of those 75 cent warrants I’d be super-po’ed right now. I looked up “screwed” in the dictionary and it said when a company has 30 million 75 cent warrants and needs their share price to go from 40 cents to a dollar in the next few weeks to avoid delisting then they are totally screwed. Really. Of course, the dictionary doesn’t know about the cunning plan to maybe someday sell drugs in Malaysia and Vietnam, maybe.
Just checking in, are we at $5 yet?
I cannot believe approval of this 25 cent drug with 10 competitors hasn't sent the SP to $5 by now. Manipulation! Probably they don't release the PR because they don't want to point out that they are about to extract over $1M cash from IPCI treasury by taking their hilarious ANDA approval bonuses.
What's a million or so pre-funded warrants among friends?
Stay tuned for the next pump: Nasal/oral HAL study results will be described in a PR as a great success, but no data will be revealed to prove it is true.
("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has submitted an investigational new drug ("IND") application to the U.S. Food and Drug Administration ("FDA") for its oxycodone hydrochloride immediate release ("IPCI006") tablets in the 5 mg, 10 mg, 15 mg, 20 mg and 30 mg strengths.
Oxycodone hydrochloride is indicated for the management of moderate to severe pain where the use of an opioid analgesic is appropriate.
This novel drug formulation incorporates the Company's Paradoxical OverDose Resistance Activating System ("PODRAS™") delivery technology and its novel Point Of Divergence Drug Delivery System ("nPODDDS™") technology.